You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行》野村升信達生物(01801.HK)目標價至89.8元 維持「買入」評級
阿思達克 06-30 10:45
野村發表研究報告,指信達生物(01801.HK)上周六(28日)在上海舉行腫瘤研發日,其中公司的重要項目IBI363(PD-1/IL2)受到重點關注。野村將IBI363的風險調整後高峰銷售額預測上調至59億元人民幣(下同),並將目標價從54.6元提升至89.8元,維持「買入」評級。 報告提及,信達生物管理層的願景是到2030年成為全球頂尖的生物製藥公司。目前該公司擁有16款商業化藥物、21個臨床項目、14萬升的製造產能及7,000名員工,並重申將於2025財年實現正EBITDA(息稅折舊攤銷前利潤),2027財年產品收入達200億元,並於2030財年有五個項目進入全球三期臨床階段。 報告指,據管理層介紹,信達研究院擁有500名研究人員,目標是每年將6至8個分子推進至臨床階段,依托其成功開發出 IBI363、IBI3003 (GPRC5D/BCMA/CD3)、IBI354 (HER2 ADC)、IBI3001 (EGFR/B7H3 ADC) 及 IBI3022 (CEACAM dp ADC) 等分子的研發平台。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account